INOTERSEN: 1,714 Adverse Event Reports & Safety Profile
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
1,714
Total FAERS Reports
127 (7.4%)
Deaths Reported
568
Hospitalizations
1,714
As Primary/Secondary Suspect
24
Life-Threatening
33
Disabilities
Oct 5, 2018
FDA Approved
Discontinued
Status
Active Ingredient: INOTERSEN SODIUM · FDA Application: 211172 ·
Patent Expires: Apr 29, 2031 · First Report: 2013 · Latest Report: 20250826
What Are the Most Common INOTERSEN Side Effects?
#1 Most Reported
Platelet count decreased
334 reports (19.5%)
#2 Most Reported
Protein urine present
269 reports (15.7%)
#3 Most Reported
Glomerular filtration rate decreased
264 reports (15.4%)
All INOTERSEN Side Effects by Frequency
| Side Effect | Reports | % of Total | Deaths | Hosp. |
|---|---|---|---|---|
| Platelet count decreased | 334 | 19.5% | 18 | 86 |
| Protein urine present | 269 | 15.7% | 7 | 48 |
| Glomerular filtration rate decreased | 264 | 15.4% | 6 | 54 |
| Urine protein/creatinine ratio increased | 249 | 14.5% | 7 | 51 |
| Blood creatinine increased | 214 | 12.5% | 6 | 46 |
| Fatigue | 198 | 11.6% | 16 | 78 |
| Bacterial test positive | 193 | 11.3% | 5 | 31 |
| Urine abnormality | 184 | 10.7% | 5 | 30 |
| Nausea | 152 | 8.9% | 10 | 67 |
| Malaise | 145 | 8.5% | 14 | 79 |
| Diarrhoea | 135 | 7.9% | 9 | 60 |
| Asthenia | 134 | 7.8% | 15 | 73 |
| Urinary casts | 127 | 7.4% | 3 | 18 |
| Pain | 124 | 7.2% | 7 | 63 |
| White blood cells urine positive | 124 | 7.2% | 3 | 18 |
| Urine leukocyte esterase positive | 123 | 7.2% | 2 | 18 |
| Chills | 121 | 7.1% | 1 | 43 |
| Haemoglobin decreased | 109 | 6.4% | 8 | 57 |
| Fall | 106 | 6.2% | 15 | 81 |
| Dizziness | 103 | 6.0% | 3 | 50 |
Who Reports INOTERSEN Side Effects? Age & Gender Data
Gender: 41.7% female, 58.3% male. Average age: 66.9 years. Most reports from: US. View detailed demographics →
Is INOTERSEN Getting Safer? Reports by Year
| Year | Reports | Deaths | Hosp. |
|---|---|---|---|
| 2013 | 3 | 0 | 0 |
| 2014 | 1 | 0 | 0 |
| 2015 | 8 | 0 | 1 |
| 2017 | 1 | 0 | 0 |
| 2018 | 25 | 2 | 4 |
| 2019 | 192 | 13 | 69 |
| 2020 | 307 | 25 | 101 |
| 2021 | 236 | 16 | 80 |
| 2022 | 134 | 17 | 62 |
| 2023 | 94 | 12 | 43 |
| 2024 | 74 | 7 | 41 |
| 2025 | 34 | 3 | 25 |
What Is INOTERSEN Used For?
| Indication | Reports |
|---|---|
| Hereditary neuropathic amyloidosis | 1,396 |
| Product used for unknown indication | 179 |
| Polyneuropathy | 62 |
| Familial amyloidosis | 52 |
| Amyloidosis | 46 |
| Cardiac amyloidosis | 12 |
| Acquired attr amyloidosis | 10 |
| Amyloidosis senile | 7 |
INOTERSEN vs Alternatives: Which Is Safer?
INOTERSEN vs INOTUZUMAB OZOGAMICIN
INOTERSEN vs INSULIN
INOTERSEN vs INSULIN ASPART
INOTERSEN vs INSULIN ASPART\INSULIN DEGLUDEC
INOTERSEN vs INSULIN BEEF
INOTERSEN vs INSULIN DEGLUDEC
INOTERSEN vs INSULIN DEGLUDEC\LIRAGLUTIDE
INOTERSEN vs INSULIN DETEMIR
INOTERSEN vs INSULIN GLARGINE
INOTERSEN vs INSULIN GLARGINE-YFGN
Official FDA Label for INOTERSEN
Official prescribing information from the FDA-approved drug label.